Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04650919

Aortic Laryngeal Rehabilitation Graft

The larynx is a cartilaginous organ of the respiratory system located in the throat, which plays an essential role in respiratory function, swallowing and sound production.

In the case of advanced tumours, the surgical option most often remains total laryngectomy, with the corollary of a major impact on quality of life, not so much because of the loss of voice, but because of the presence of a definitive tracheostoma with particularly deleterious consequences.

The majority of the work of the different teams around the world has focused on restoring phonatory function, but no technique - apart from the artificial larynx developed in the ENT department of the Hautepierre Hospital - has yet succeeded in removing the tracheotomy orifice, requiring the restoration of a common passage between the respiratory and swallowing passages. If nutrition and phonatory function can still be supplemented after such an operation (oesophageal rehabilitation, implant placed between the trachea and oesophagus), natural breathing is no longer possible. Patients are forced to wear a permanent tracheotomy opening.

There are currently only 2 ways to try to restore all the functions of the larynx after total laryngectomy: i) laryngeal transplantation, but this procedure requires maintaining immunosuppressive treatment, which is not possible in patients suffering from cancer of the larynx, which is not a vital organ, ii) artificial larynx made of biomaterials (titanium), the first cases of which were performed worldwide in the ENT department of the Strasbourg University Hospital in 2012, results published in the NEJM (API 2008-2009 HUS No. 4493- IDRCB No.: 2011-A00032-39. However, difficulties were encountered with the use of the titanium prosthesis due to the bulk and rigidity of the removable and non-removable part, which caused residual swallowing difficulties (false routes).

It is now possible, due to the development of new allograft techniques in humans for tracheal replacement (studies published on a large number of cases with several years of hindsight, cf. references), to switch to the "all biological" using an aortic graft stented with a silicone stent. We wish to use these grafts in laryngeal restoration after total laryngectomy by our team, while exploiting all the data and experience acquired (unique in the world) within the ENT department of Hautepierre Hospital. This new conceptual leap should make it possible to significantly improve the patient's quality of life and the performance previously acquired in clinical trials on the artificial larynx in its entirety (breathing, phonation) or partially (swallowing).

The investigators thus propose to evaluate this new artificial larynx in aortic allograft, the objective of which is to supplement the respiratory, swallowing and phonation functions in patients laryngectomized for carcinological causes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ENT department-Hôpitaux Universitaires de Strasbourg

Strasbourg, 67098, France

Location status: Recruiting

Location contact

Christian DEBRY, MD PhD

CONTACT

Christian DEBRY, MD PhD

PRINCIPAL_INVESTIGATOR

Esteban BRENET, MD

SUB_INVESTIGATOR

Idir DJENNAOUI, MD

SUB_INVESTIGATOR

Lea FATH, MD

SUB_INVESTIGATOR

Patrick HEMAR, MD PhD

SUB_INVESTIGATOR

Philippe SCHULTZ, MD PhD

SUB_INVESTIGATOR

Sait CIFTCI, MD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with carcinomatous pathology of the upper airways requiring total laryngectomy
  • Patient affiliated to a social health insurance scheme (beneficiary or beneficiary's successor)
  • Patient speaks and reads French, understands the objectives and risks of the research and is able to provide dated and signed informed consent.
  • Patient having been informed of the results of the prior medical examination
  • For a woman with the ability to procreate: negative blood pregnancy test (verified during preoperative blood work) and effective contraception throughout the study.

Exclusion criteria

  • Patient with a contraindication to general anaesthesia and/or iodinated contrast agents
  • Breastfeeding woman
  • Patient with a WHO performance index of grade strictly greater than 2 at the inclusion visit
  • Patient with subglottic or basi-lingual tumour extension greater than 1 cm (by endoscopic control and CT scan)
  • Patient having undergone cervico-facial radiotherapy prior to surgical management
  • Patient suffering from severe coagulation disorders (checked during the blood test performed as part of the standard care to make the diagnosis of cancer)
  • Patient with a history of allergy to DMSO, DHEA, clindamycin, gentamicin, vancomycin used for graft treatment and preservation
  • Inability to give informed information about the patient (patient in emergency situations, difficulties in understanding the patient)
  • Patient in exclusion period (determined by a previous or ongoing study)
  • Patient under safeguard of justice
  • Patient under guardianship,curatorship, family guardianship
  • Any situation considered by the operating physician as falling under a non-inclusion criterion
  • Patient suffering from a decompensated psychiatric pathology or at risk of decompensation, which may interfere with the follow-up modalities in the research setting.

Treatment and study plan

Total laryngectomy and reconstruction by stented aortic allograft (using human tissue and device).

Procedure

The procedure consists of 2 operating times:

  • Surgery S1 (1st surgical procedure): total laryngectomy and placement of the stented aortic graft (human tissue + device: NOVATECH GSS TM (trademark) TD), under tracheotomy cover.
  • Surgery S2 (2nd surgical procedure) (between S1 +24 weeks and S1 +36 weeks) : opening of the proximal part of the graft by endoscopic way with maintenance of the tracheotomy orifice to ensure patient safety.

Primary outcomes

  1. Success or Failure of the procedure

    Time frame: 6 month following the second surgery (Month 6; Visit 6)

    The primary endpoint is composite, combining clinically assessments:

    • the score on the Respiratory Function Assessment (clinically assessed : 0: no dyspnea, to 3 (major dyspnea) and
    • the score (0-3) on the Swallowing Ability Assessment (0: no issue to 3: major food misdirection) assessed by nasofibroscopy.

    The procedure will be considered a success if :

    • respiratory function: no dyspnea (score=0) or moderate dyspnea (score=1) AND
    • swallowing ability: no false-route (score=0) or moderate false-route (score=1)

    In all other cases, the procedure will be considered a failure.

Secondary outcomes

  1. Scoring of dyspnea at each follow-up visit

    Time frame: 1 to 8 days and15 days following the second surgery (Visit 3), Month 1 (Visit 4), Month 3 (Visit 5), Month 6 (Visit 6), Month 9 (Visit 7) and Month 12 (Visit 8)

    Score on the Respiratory Function Assessment (clinically assessed : 0: no dyspnea, to 3 (major dyspnea)

  2. Scoring of swallowing ability assessment at each follow-up visit

    Time frame: 8 days and 15 days following the second surgery (Visit 3), Month 1 (Visit 4), Month 3 (Visit 5), Month 6 (Visit 6), Month 9 (Visit 7) and Month 12 (Visit 8)

    Score (0-3) on the Swallowing Ability Assessment (0: no issue to 3: major food misdirection) assessed by nasofibroscopy.

  3. Evaluation of the patient's voice by the "Voice Handicap Index 30" (Pommée, 2018)

    Time frame: 8 days and 15 days following the second surgery (Visit 3), Month 1 (Visit 4), Month 3 (Visit 5), Month 6 (Visit 6), Month 9 (Visit 7) and Month 12 (Visit 8)

    The Voice Handicap Index is a scale where the patient grades the severity of his disorder by 10 items on a scale from 0 (never) to 4 (always). Close to 0 may consider that the disability is almost nil, close to 120 the patient's voice has a significant impact on his or her daily life.

  4. Analysis of Adverse Events and Serious adverse Events throughout the study

    Time frame: From the signature of the consent form (inclusion visit) to the end of study visit, up to 28 months.

Study contacts

Contact information is provided by the study sponsor or research team.

Christian DEBRY, MD PhD

CONTACT

[email protected]

+33 (0)3 88 12 76 44

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Collaborators

  • Etablissement Français du Sang

Registry information

Official study title

Placement of a Laryngeal Allograft Aortic Implant After Total Laryngectomy to Rehabilitate Laryngeal Function

Acronym: GRAAL

Important dates

Study start
2021
Primary completion
2025
Study completion
2026
First posted
Dec 3, 2020
Registry last updated
Dec 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.